New hope for rare blood cancer: drug trial targets tumor growth

NCT ID NCT05592015

Recruiting now Disease control Sponsor: Jonathan Brammer Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated May 24, 2026 · Updated 25 times

Summary

This study tests a pill called ruxolitinib in 30 adults with a rare type of leukemia (T-LGLL). The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and improve quality of life, while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA